Health Catalyst (NASDAQ:HCAT) Stock Rating Lowered by Evercore ISI

Health Catalyst (NASDAQ:HCAT - Get Free Report) was downgraded by Evercore ISI from an "outperform" rating to an "inline" rating in a research note issued to investors on Wednesday,Briefing.com Automated Import reports.

A number of other research firms also recently commented on HCAT. KeyCorp upgraded Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective for the company in a report on Wednesday, January 8th. Citigroup dropped their price target on Health Catalyst from $10.50 to $10.00 and set a "buy" rating for the company in a research note on Friday, January 10th. Stephens reduced their price objective on Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Thursday, March 6th. Canaccord Genuity Group dropped their target price on shares of Health Catalyst from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, January 21st. Finally, Royal Bank of Canada reduced their price target on shares of Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $8.73.

Health Catalyst Trading Down 3.3 %

Health Catalyst stock traded down $0.13 during trading on Wednesday, reaching $3.80. The company had a trading volume of 145,292 shares, compared to its average volume of 615,089. Health Catalyst has a 12-month low of $3.60 and a 12-month high of $9.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The stock's 50 day moving average price is $4.65 and its two-hundred day moving average price is $6.50. The firm has a market capitalization of $266.80 million, a price-to-earnings ratio of -2.81 and a beta of 1.43.

Insiders Place Their Bets

In related news, COO Daniel Lesueur sold 5,209 shares of the business's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $5.76, for a total value of $30,003.84. Following the transaction, the chief operating officer now owns 86,044 shares in the company, valued at approximately $495,613.44. The trade was a 5.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Linda Llewelyn sold 6,442 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $5.80, for a total value of $37,363.60. Following the completion of the transaction, the insider now directly owns 92,260 shares of the company's stock, valued at $535,108. This represents a 6.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,030 shares of company stock worth $263,269 in the last quarter. 2.50% of the stock is owned by corporate insiders.

Institutional Trading of Health Catalyst

Several institutional investors have recently added to or reduced their stakes in HCAT. Impax Asset Management Group plc increased its position in shares of Health Catalyst by 7.7% in the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock worth $19,442,000 after purchasing an additional 195,525 shares during the last quarter. Geode Capital Management LLC grew its stake in Health Catalyst by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company's stock worth $11,749,000 after purchasing an additional 66,896 shares in the last quarter. State Street Corp increased its holdings in Health Catalyst by 2.5% in the third quarter. State Street Corp now owns 1,163,754 shares of the company's stock valued at $9,473,000 after buying an additional 28,251 shares during the last quarter. Intech Investment Management LLC raised its stake in Health Catalyst by 59.7% during the fourth quarter. Intech Investment Management LLC now owns 28,386 shares of the company's stock valued at $201,000 after buying an additional 10,611 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Health Catalyst during the 4th quarter worth approximately $2,044,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.